Cue Biopharma, Inc. (CUE) shareholders
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.12−1.38 (-7.89%)
Close on Nov 13, 2026Market cap $117.10MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
22.6%
2M of 7M shares
Institutional holders
49
48 new, 1 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
5 buys · 15 sales
Net sold $2.33M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Andrew Gundlach Joint filing with Bleichroeder LP (9.99%), Bleichroeder Holdings LLC (9.99%) | 6,127,662 | 9.99% | 13G (passive) amendment | Mar 19, 2025 |
| Bleichroeder LP Joint filing with Bleichroeder Holdings LLC (8.77%), Andrew Gundlach (8.77%) | 663,009 | 8.77% | 13G (passive) amendment | Sep 30, 2026 |
| Mark E. Strome Joint filing with Strome Group, Inc. (8.48%), Strome Investment Management, LP (8.48%) and 1 more | 644,916 | 8.50% | 13G (passive) amendment | Jul 14, 2026 |
| Shao-Lee Lin | 467,166 | 6.20% | 13D (active) | May 3, 2026 |
| Driehaus Capital Management LLC | 292,144 | 6.96% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CUE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bleichroeder LP | 370,682 | 5.10% | $11.70M | New | 2.09% |
| Driehaus Capital Management LLC | 292,144 | 4.02% | $9.22M | New | 0.05% |
| Vanguard Capital Management LLC | 161,700 | 2.23% | $5.10M | New | 0.00% |
| Ikarian Capital, LLC | 104,364 | 1.44% | $3.29M | New | 0.35% |
| TFG Asset Management GP Ltd | 93,819 | 1.29% | $2.96M | New | 0.47% |
| Stempoint Capital LP | 66,995 | 0.92% | $2.11M | New | 0.36% |
| BlackRock, Inc. | 57,807 | 0.80% | $1.82M | New | 0.00% |
| ADAR1 Capital Management, LLC | 55,193 | 0.76% | $1.74M | New | 0.08% |
| Lion Point Capital, LP | 52,928 | 0.73% | $1.67M | New | 7.99% |
| Squadron Capital Management LLC | 50,000 | 0.69% | $1.58M | New | 0.49% |
| Diadema Partners LP | 48,369 | 0.67% | $1.53M | New | 0.19% |
| Geode Capital Management, LLC | 47,824 | 0.66% | $1.51M | New | 0.00% |
| Boothbay Fund Management, LLC | 31,459 | 0.43% | $992.85K | New | 0.01% |
| UBS Group AG | 26,700 | 0.37% | $842.65K | New | 0.00% |
| Citadel Advisors LLC | 25,633 | 0.35% | $808.98K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 24,476 | 0.34% | $772.46K | New | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 22,881 | 0.31% | $722.12K | New | 0.04% |
| Renaissance Technologies LLC | 14,689 | 0.20% | $463.59K | New | 0.00% |
| Persistent Asset Partners Ltd | 12,332 | 0.17% | $389.20K | New | 0.12% |
| Robertson Stephens Wealth Management, LLC | 11,133 | 0.15% | $351.36K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 49 | 2M | 22.6% | 48 / 0 | 0 / 1 | 2M | 0M |
| Q1 2026 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
13 funds held CUE in Q2 2026, 84% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CUE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 111,867 | 1.54% | $3.53M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 47,090 | 0.65% | $1.49M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 16,031 | 0.22% | $351.08K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 11,129 | 0.15% | $351.23K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 5,783 | 0.08% | $126.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,812 | 0.07% | $105.38K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 1,815 | 0.02% | $48.71K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 1,724 | 0.02% | $54.41K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 1,019 | 0.01% | $32.16K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 975 | 0.01% | $21.35K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 747 | 0.01% | $23.58K | 0.01% | Jun 30, 2026 |
| Avantis U.S. Small Cap Equity ETF | 300 | 0.00% | $6.57K | 0.00% | May 31, 2026 |
| Dimensional US Core Equity Market ETF | 116 | 0.00% | $3.11K | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 105 | 0.00% | $2.82K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 59 | 0.00% | $1.86K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shao-Lee Lin | Chief Executive Officer, Director | 694,908 | 9.57% | Oct 14, 2026 |
| Usman Azam | CHIEF EXECUTIVE OFFICER, Director | – | – | Oct 2, 2025 |
| Daniel R. Passeri | CHIEF EXECUTIVE OFFICER, Director | 164,578 | 2.27% | Mar 25, 2025 |
| Sumita Ray | Chief Legal Compliance Officer | 116,701 | 1.61% | Oct 14, 2026 |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | 47,817 | 0.66% | Oct 14, 2026 |
| James M. Ahlers | Chief Financial Officer | 25,500 | 0.35% | Aug 3, 2026 |
| Dominique Christian Borie | Chief Medical Officer | 31,500 | 0.43% | Jul 15, 2026 |
| Lucinda Warren | CHIEF BUSINESS OFFICER | – | – | Apr 10, 2026 |
| Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | – | – | Apr 10, 2026 |
| Colin Sandercock | SVP, GENERAL COUNSEL | 30,499 | 0.42% | Apr 10, 2026 |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | 14,311 | 0.20% | Mar 25, 2025 |
| Matteo Levisetti | Chief Medical Officer | 9,230 | 0.13% | Mar 25, 2025 |
| Pamela Garzone | Director | 18,900 | 0.26% | Aug 28, 2026 |
| Pasha Sarraf | Director | 29,195 | 0.40% | Aug 28, 2026 |
| Daniel A. Camardo | Director | 21,800 | 0.30% | Jul 10, 2026 |
| Viola Mong Meehan | Director | 21,800 | 0.30% | Jul 10, 2026 |
| Frank Morich | Director | 28,000 | 0.39% | Jan 6, 2026 |
| Patrick Verheyen | Director | 8,174 | 0.11% | Jan 6, 2026 |
| Peter A. Kiener | Director | 357 | 0.00% | Jan 6, 2026 |
| Jill Marie Broadfoot | Director | – | – | Jan 6, 2026 |
| Frederick W. Driscoll | Director | 0 | – | Jan 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Oct 12, 2026 | Sale | −1,144 | $28.05 | $32.09K | 47,817 |
| Shao-Lee Lin Chief Executive Officer, Director | Oct 12, 2026 | Sale | −1,087 | $28.05 | $30.49K | 694,908 |
| Shao-Lee Lin Chief Executive Officer, Director | Oct 12, 2026 | Sale | −10,000 | $27.50 | $275.00K | 695,995 |
| Sumita Ray Chief Legal Compliance Officer | Oct 12, 2026 | Sale | −1,844 | $28.05 | $51.72K | 116,701 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Sale | −4 | $31.13 | $125 | 118,545 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Sale | −6,442 | $30.35 | $195.51K | 118,549 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Option exercise | +18,196 | – | – | 127,374 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Sale | −2,383 | $29.37 | $69.99K | 124,991 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Sale | −1,519 | $29.37 | $44.61K | 53,070 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Sale | −4,106 | $30.35 | $124.62K | 48,964 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Sale | −3 | $31.13 | $93 | 48,961 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Option exercise | +13,647 | – | – | 54,589 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 13, 2026 | Sale | −2,375 | $28.11 | $66.76K | 716,455 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 13, 2026 | Sale | −10,460 | $29.48 | $308.36K | 705,995 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 13, 2026 | Sale | −5,423 | $27.19 | $147.45K | 718,830 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale | −5,775 | $27.75 | $160.26K | 724,253 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 12, 2026 | Option exercise | +109,179 | – | – | 764,253 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale | −34,225 | $26.99 | $923.73K | 730,028 |
| James M. Ahlers Chief Financial Officer | Jul 30, 2026 | Award | +25,500 | – | – | 25,500 |
| Dominique Christian Borie Chief Medical Officer | Jul 13, 2026 | Award | +31,500 | – | – | 31,500 |
| Pasha Sarraf Director | Jul 9, 2026 | Award | +18,400 | – | – | 29,195 |
| Pamela Garzone Director | Jul 9, 2026 | Award | +18,900 | – | – | 18,900 |
| Pasha Sarraf Director | Jul 9, 2026 | Award | +21,800 | – | – | 32,595 |
| Sumita Ray Chief Legal Compliance Officer | Jul 9, 2026 | Award | +54,589 | – | – | 109,178 |
| Shao-Lee Lin Chief Executive Officer, Director | Jul 9, 2026 | Award | +327,537 | – | – | 655,074 |
| Daniel A. Camardo Director | Jul 9, 2026 | Award | +21,800 | – | – | 21,800 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Jul 9, 2026 | Award | +40,942 | – | – | 40,942 |
| Viola Mong Meehan Director | Jul 9, 2026 | Award | +21,800 | – | – | 21,800 |
| Pamela Garzone Director | Jul 9, 2026 | Award | +21,800 | – | – | 21,800 |
| Shao-Lee Lin CHIEF EXECUTIVE OFFICER, Director | May 3, 2026 | Award | +327,537 | – | – | 327,537 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +78,116 | $0.31 | $24.22K | 246,440 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +4,229 | $0.31 | $1.31K | 4,229 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +77,148 | $0.30 | $23.14K | 81,377 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +86,947 | $0.32 | $27.82K | 168,324 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +77,417 | $0.30 | $23.23K | 323,857 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Buy | +30,000 | $1.03 | $30.90K | 164,578 |
| Anish Suri PRESIDENT AND CSO | Aug 25, 2023 | Buy | +4,000 | $2.76 | $11.04K | 135,638 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Aug 14, 2023 | Buy | +3,000 | $2.86 | $8.58K | 134,578 |
| Peter A. Kiener Director | Mar 23, 2023 | Sale | −9,325 | $3.28 | $30.59K | 357 |
| Peter A. Kiener Director | Mar 23, 2023 | Option exercise | +9,682 | $2.86 | $27.69K | 9,682 |
| Kerri-Ann Millar CHIEF FINANCIAL OFFICER | Aug 22, 2022 | Tax withholding | −2,828 | $3.05 | $8.63K | 14,311 |
| Kerri-Ann Millar CHIEF FINANCIAL OFFICER | Aug 21, 2022 | Option exercise | +6,667 | – | – | 17,139 |
| Cameron Gray Director | Jun 14, 2022 | Tax withholding | −51,562 | $3.20 | $165.00K | 687,049 |
| Cameron Gray Director | Jun 14, 2022 | Option exercise | +61,111 | $2.70 | $165.00K | 738,611 |
| Frank Morich Director | May 27, 2022 | Buy | +28,000 | $3.75 | $105.00K | 28,000 |
| Aaron G.L. Fletcher Director | May 24, 2022 | Buy | +55,000 | $3.34 | $183.70K | 940,000 |
| Aaron G.L. Fletcher Director | May 23, 2022 | Buy | +150,000 | $3.52 | $528.00K | 885,000 |
| Aaron G.L. Fletcher Director | Mar 31, 2022 | Buy | +735,000 | $4.76 | $3.50M | 735,000 |
| Anish Suri PRESIDENT AND CSO | Mar 31, 2022 | Option exercise | +16,668 | – | – | 110,706 |
| Anish Suri PRESIDENT AND CSO | Mar 31, 2022 | Tax withholding | −7,068 | $4.88 | $34.49K | 103,638 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Mar 31, 2022 | Option exercise | +75,000 | – | – | 173,700 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Mar 31, 2022 | Gift | −10,000 | – | – | 131,578 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Mar 31, 2022 | Tax withholding | −32,122 | $4.88 | $156.76K | 141,578 |
| Peter A. Kiener Director | Nov 16, 2021 | Option exercise | +1,361 | $2.86 | $3.89K | 1,361 |
| Peter A. Kiener Director | Nov 16, 2021 | Sale(10b5-1 plan) | −1,361 | $18.02 | $24.53K | 0 |
| Peter A. Kiener Director | Nov 15, 2021 | Sale(10b5-1 plan) | −18,815 | $17.92 | $337.16K | 0 |
| Peter A. Kiener Director | Nov 15, 2021 | Option exercise | +18,815 | $2.86 | $53.81K | 18,815 |
| Anish Suri President and CSO | Nov 15, 2021 | Option exercise | +8,000 | $8.26 | $66.08K | 102,038 |
| Anish Suri President and CSO | Nov 15, 2021 | Sale(10b5-1 plan) | −8,000 | $18.05 | $144.40K | 94,038 |
| Anish Suri President and CSO | Nov 11, 2021 | Option exercise | +20,000 | $6.42 | $128.40K | 114,038 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
14.38%
1M shares short
Days to cover
7.6
At 0M shares a day
Change since last report
+8.9%
From 1M shares
Short volume, 20 days
54.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cue Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 107,024 shares on Sep 23, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shao-Lee Lin Officer, Director | Oct 13, 2026 | 11,087 | $305.49K | Oct 12, 2026 | Restricted Stock Units vesting under registered plan |
| Sumita Ray Officer, CORPORATE SECRETARY | Oct 13, 2026 | 1,844 | $51.72K | Oct 12, 2026 | Restricted Stock Units vesting under registered plan |
| Shao-Lee Lin Officer, Director | Aug 14, 2026 | 58,258 | $1.60M | Aug 12, 2026 | Restricted Stock Units vesting under registered plan |
| Sumita Ray Officer, CORPORATE SECRETARY | Aug 13, 2026 | 8,829 | $266.11K | Aug 13, 2026 | Restricted Stock Units vesting under registered plan |
| Matteo Levisetti Officer | Dec 29, 2025 | 7,230 | $1.91K | Dec 29, 2025 | Open Market Purchase |
See a number that looks wrong?